SUNNYVALE, Calif., Oct. 21, 2019 /PRNewswire/ -- Accuray
Incorporated (Nasdaq: ARAY) announced today that Suzanne Winter has joined the company as Senior
Vice President, Chief Commercial Officer effective October 21, 2019. Ms. Winter will have global
responsibility for the commercial function reporting to Accuray's
President and CEO, Joshua
Levine.
Ms. Winter has more than 25 years of medical technology
experience in senior executive roles spanning general management,
commercial operations, and strategic business development across a
range of healthcare industry segments, including radiology,
neurology and surgery. Most recently, she served as Group Vice
President – Americas Region at Medtronic Diabetes, where she led
the $1.4 billion diabetes business
for the United States,
Canada and Latin America sub-regions. Previously,
she was the General Manager of GE Healthcare's Detection and
Guidance Solutions operations.
"We are excited to welcome Suzanne as our Chief Commercial
Officer at this important point in time in Accuray's strategic
evolution. She has established a reputation for consistently
achieving business goals focused on profitable revenue growth and
is a proven leader with a deep commercial expertise in delivering
innovative, market-driven products that have improved patient care
and positively impacted corporate financial performance," said Mr.
Levine. "Accuray has a solid foundation on which to build, and I
believe that Suzanne's background and skills will result in
accelerated growth in our business moving forward."
"At Accuray, improving the treatment experience and outcomes for
cancer patients has been a core element in the company's business
history and philosophy. I share this commitment to improving
patient's lives having spent the bulk of my career bringing
clinically innovative products and solutions to patients across a
wide range of medical device market segments. I look forward to
guiding the organization's commercial execution and expanding
access to Accuray's radiation therapy solutions," said Suzanne Winter, Senior Vice President, Chief
Commercial Officer.
About Accuray
Accuray Incorporated (Nasdaq: ARAY) develops, manufactures and
sells radiotherapy systems that are intended to make cancer
treatments shorter, safer, personalized and more effective,
ultimately enabling patients to live longer, better lives. Our
radiation treatment delivery systems in combination with
fully-integrated software solutions set the industry standard for
precision and cover the full range of radiation therapy and
radiosurgery procedures. For more information, please visit
www.accuray.com or follow us on Facebook, LinkedIn, Twitter
and YouTube.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to expectations regarding the
company's business, foundation, momentum, and growth, expectations
regarding the impact of the company's new chief commercial officer,
and expectations regarding the expansion of access to the company's
radiation therapy solutions. These forward-looking statements
involve risks and uncertainties. If any of these risks or
uncertainties materialize, or if any of the company's assumptions
prove incorrect, actual results could differ materially from the
results expressed or implied by these forward-looking statements.
These risks and uncertainties include, but are not limited to, the
company's ability to achieve widespread market acceptance of its
products, the ability of customers in China to obtain
Class A or B user licenses to purchase radiotherapy
systems, the company's ability to achieve profitability by
maintaining or increasing gross margins on its products sales and
services, the company's ability to anticipate or keep pace with
changes in the marketplace and the direction of technological
innovation and customer demands and such other risks identified
under the heading "Risk Factors" in the company's annual report on
Form 10-K, filed with the Securities and Exchange Commission (the
"SEC") on August 23, 2019, and as
updated periodically with the company's other filings with the
SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to the
company at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.
Investor Contact:
Michael Polyviou
Investor Relations, EVC Group
+1 (732) 933-2755
mpolyviou@evcgroup.com
Media Contact:
Beth
Kaplan
Public Relations Director, Accuray Incorporated
+1 (408)
789-4426
bkaplan@accuray.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/accuray-appoints-medtech-veteran-suzanne-winter-as-chief-commercial-officer-300941458.html
SOURCE Accuray Incorporated